The present invention discloses various parenteral pharmaceutical formulations having a protracted effect, which comprise: a sterile aqueous suspension of about 20 U/mL to about 500 U/mL insulin analog, about 5 mg/mL to about 10 mg/mL sodium chloride, about 0.2 to about 2.0 mg/mL physiologically acceptable buffer, a zinc ion content of about 0.07 mg/mL to about 0.1 mg/mL, and a physiologically acceptable preservative at a pH of about 6.5 to about 7.8; such that less than 5% of the analog present in the suspension is in the dissolved state. 0 Lilly Corporate Center, City of Indianapolis, State of Indiana, U.S.A. Eli Lilly & Company., 566/CAL/1996 566/CAL/1996 INDIA 2009-03-25T18:00:13Z 2005-03-04 1996-03-25 410455 C 07 K 14/62 | C 07 K 1/32 1) Michael Rosario De Felippis 2) Bruce Hill Frank -2 0 2209 USA 1995-03-31 08/414,880 2005-03-04 0 3pCzCCju 2009-04-30T18:54:39Z 126908 1) MICHAEL ROSARIO DE FELIPPIS 2) BRUCE HILL FRANK 100496 ELI LILLY & COMPANY